2025年3月27日，制药公司默沙东（MRK）成交额为10.84亿美元，在当日美股中排第54名，成交额较昨日减少11.13%，当日成交量为1235.73万。 默沙东（MRK）于2025年3月27日跌0.58%，报87.6美元，该股过去5个交易日跌7.53%，整个3月跌5.04%，年初至今跌11.94%，过去52周跌33.51%。

We recently published a list of 10 Low Volatility Stocks to Buy According to Billionaire Ken Fisher. In this article, we are ...

Investors’ deep pessimism is actually bullish, and less regulatory constraint could fuel new drug approvals and M&A.

Investing.com -- According to Reuters, several drugmakers have reportedly begun accelerating shipments of medicines to the United States in response to potential tariff threats from President Donald ...

The FDA is due to make an approval decision on injectable Keytruda by mid-September. The move could bolster downtrodden Merck stock.

Merck (NYSE: MRK) is a top healthcare company with one of the best drugs ever made in its portfolio: Keytruda. During the ...

Healthcare stocks have been out of vogue with investors since late 2022. Myriad reasons underlie the negative sentiment ...

Eli Lilly and Company, AbbVie, Merck & Co., Inc., Pfizer, D-Wave Quantum, Johnson & Johnson, and Amgen are the seven ...

We recently published a list of Jim Cramer Focused On These 9 Stocks Recently. In this article, we are going to take a look ...

Merck's revenues are driven by cancer med Keytruda, which faces patent expiry by 2028. See why I rate MRK stock a hold.

The U.S. stock market had a mixed session on Tuesday. The Nasdaq Composite climbed nearly 80 points, or 0.5%, closing at ...